Vera Therapeutics Announces New Atacicept Phase 2 Clinical
Atacicept is the first known investigational therapy to decrease both circulatory Gd-IgA1 and anti-Gd-IgA1 autoantibodies which correlate with increased risk of IgA nephropathy disease progressionNew analysis shows atacicept improved renal ...